Dr. Frances Shepherd CV - (NCRI) is

118. Giuliani ME, Atallah S, Sun A. Bezjak A, Le LW, Brade A, Co J, Leighl NB,
Tsao MS, Leighl NB, Shepherd FA, Hope AJ, Clinical outcomes of extensive stage
small cell lung carcinoma patients treated with consolidative thoracic radiotherapy, Clin
Lung Cancer. 2011; 12: 375-9 .
119. Ellis PM, Blais N, Soulieres D, lonescu DN, Kashyap M, Liu G, Melosky B,
Reiman T, Romeo P, Shepherd FA, Tsao MS, Leighl NB. A systematic review and
Canadian concensus recommendations on the use of biomarkers in the treatment of nonsmall
cell lung cancer. J Thorac Oncol 2011; 8: 1379-91
120. Shepherd FA. Molecular selection trumps clinical selection. J Clin Oncol.
2011; 29: 2843-4
121. Cuffe S, Moua T. Summerfield R, Roberts H, Jett J, Shepherd FA.
Characteristics and outcomes of small cell lung cancer patients diagnosed during two
lung cancer computed tomographic screening programs in heavy smokers. J Thorac
Oncol. 2011; 6: 818-22
122. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E. Nicholson AG, Shepherd
FA. Non-small-cell lung cancer. Lancet. 2011; 378: 1727-40
123. Liu G, Gramling S, Munoz D, Cheng D, Azad AK, Mirshams M, ChenZ, Xu W,
Roberts H, Shepherd FA, Tsao MS, Reisman D. Two novel BRM insertion promoter
sequence variants are associated with loss of BRM expression and lung cancer risk.
Oncogene, 2011; 30: 3295-304
124. Navab R, Strumpf D, Bandarchi B, Zhu CQ, Pintilie M, Ramnarine VR,
Ibrahimov E, Radulovich N Leung L, Barczyk M, Panchal D, To C, Yun JJ, Der S,
Shepherd FA, Jurisica I, Tsao MS. Prognostic gene-expression signature of carcinomaassociated
fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U.S.A. 2011;
108: 7160-5
125. Horgan AM, Bradbury PA, Amir E. Ng R, Douillard JY, Kim ES, Shepherd FA,
Leighl NB. An economic analysis of the INTEREST trial, a randomized trial of
docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell
cancer. Ann Oncol 2011; 8: 1805-11
126. Lara PN Jr, Longmate J, Reckamp K, Gititz B, Argiris A, Ramalingam S, Belani
CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR.
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in
advanced non-small cell lung cancer: a California cancer consortium trial. Clin Lung
Cancer 2011; 12: 33-7
127. John T, Kohler D, Pintilie M, Yanagawa N, Pham NA, Li M, Panchal D, Hui F,
Meng F, Shepherd FA, Tsao MS. The Ability to Form Primary Tumour Xenografts is
Predictive of Increased Risk of Disease Recurrance in Early Stage Non- small Cell Lung
Cancer. Clin Cancer Res. 2011; 17: 134-41.
128. Jang RW, Isogai PK, Mittmann N, Bradbury PA, Shepherd FA, Feld R, Leighl
NB. Derivation of utility values from European Organization for Research and
Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer. J
Thorac Oncol. 2010; 5: 1953-7.
129. Coate LE, Massey C, Hope A, Sacher A, Barrett K, Pierre A, Leighl N, Brade A,
de Perrot M, Waddell T, Liu G, Feld R, Burkes R, Cho BC, Darling G, Sun A. Keshavjee
S, Bezjak, Shepherd FA. Treatment of the elderly when cure is the goal: the influence
of age on treatment selection and efficacy for stage III non-small cell lung cancer. J
Thorac Oncol. 2011; 6: 537-44.
130. Wei Y, Tong J, Taylor P, Strumpf D, et al, Jurisica I, Shepherd FA, Tsao MS,
Kislinger T, Moran MF. Primary tumour xenografts of of human lung adenocarcinoma
and squamous cell carcinoma express distinct proteomic signatures. J Proteome Res
2011; 10: 161-74.
14